A damaging trial failure in December wiped 70% off the share price of BioAge Labs (Nasdaq: BIOA), a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.
The Californian company announced the discontinuation of the ongoing STRIDES Phase II study investigating BioAge’s drug candidate azelaprag as monotherapy and in combination with Eli Lilly’s (NYSE: LLY) Mounjaro/Zepbound (tirzepatide).
Azelaprag is an orally available small molecule agonist of APJ. The decision was made after liver transaminitis without clinically significant symptoms was observed in some subjects receiving in the obesity study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze